Acadian Asset Management’s Ensysce Biosciences ENSC Stock Holding History

Acadian Asset Management’s Portfolio ENSC Stock Details ENSC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-148	Closed	-$19K	–	1800
2022 Q4	$19K	Buy	+148	New	+$70.3K	﹤0.01%	1718

Other funds holding ENSC

Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return

PIA

Powell Investment Advisors Miami, Florida $317M AUM 26.57% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

ASN

Advisory Services Network Atlanta, Georgia $8.83B AUM 38.5% 1-Year Est. Return

PMFA

Plante Moran Financial Advisors Southfield, Michigan $2.15B AUM 22.82% 1-Year Est. Return

WAM

Wolverine Asset Management Chicago, Illinois $11.4B AUM 5.65% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Acadian Asset Management's ENSC Position: Q1 2023 in Review

Acadian Asset Management sold out of Ensysce Biosciences (ENSC) in Q1 2023, closing a stake of 148 shares — an estimated $19K sold.

Acadian Asset Management first reported a position in ENSC in Q4 2022 and held it in 1 quarter. The position peaked at $19K in Q4 2022. 8 funds tracked by Wall St. Rank hold ENSC as of Q1 2023.

Acadian Asset Management reported no remaining Ensysce Biosciences position as of Q1 2023 after selling out during the quarter.
Acadian Asset Management sold 148 Ensysce Biosciences shares in Q1 2023, an estimated $19K.
Acadian Asset Management first reported a position in Ensysce Biosciences in Q4 2022 and held it in 1 quarter.
Acadian Asset Management's Ensysce Biosciences position peaked at $19K in Q4 2022.
8 funds tracked by Wall St. Rank held Ensysce Biosciences as of Q1 2023.

Based on Acadian Asset Management's 13F filing for Q1 2023, filed 11 May 2023.